1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on September 12, 2025

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
REGN

Zacks

a day ago

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership
REGN

BioPharma Dive

2 days ago

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.
REGN

Pharma Voice

2 days ago

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
REGN

Benzinga

3 days ago

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Regeneron’s cat and birch allergy mAbs score in Phase III trials
REGN

Clinical Trials Arena

3 days ago

Regeneron’s cat and birch allergy mAbs score in Phase III trials

REGN

MT Newswires

3 days ago

Regeneron Says 5-Year Data Show Libtayo Improved Survival Outcomes in Lung Cancer

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
REGN

GlobeNewswire

3 days ago

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

Health Care Roundup: Market Talk
REGN

The Wall Street Journal

3 days ago

Health Care Roundup: Market Talk

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
REGN

Zacks

4 days ago

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
REGN

Zacks

4 days ago

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

REGN

MT Newswires

4 days ago

Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
REGN

GlobeNewswire

4 days ago

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

2 Beaten-Down Stocks to Buy on the Dip
REGN

Motley Fool

5 days ago

2 Beaten-Down Stocks to Buy on the Dip

How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story
REGN

Simply Wall St.

6 days ago

How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
REGN

GlobeNewswire

8 days ago

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
REGN

Insider Monkey

8 days ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
REGN

Zacks

8 days ago

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
REGN

Investor's Business Daily

8 days ago

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'

Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
REGN

StockStory

8 days ago

Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
REGN

Zacks

9 days ago

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?
REGN

Barchart

9 days ago

How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT
REGN

Insider Monkey

10 days ago

Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT

Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
REGN

Business Wire

10 days ago

Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

REGN

MT Newswires

10 days ago

DBS Bank Adjusts Price Target on Regeneron Pharmaceuticals to $720 From $760, Maintains Buy Rating

Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks
REGN

Insider Monkey

14 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks

FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma
REGN

Insider Monkey

15 days ago

FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma

Regeneron tees up myasthenia gravis drug approval after Phase III victory
REGN

Clinical Trials Arena

16 days ago

Regeneron tees up myasthenia gravis drug approval after Phase III victory

What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?
REGN

Barchart

16 days ago

What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?

REGN

MT Newswires

16 days ago

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $781 From $753, Maintains Outperform Rating

REGN

MT Newswires

16 days ago

Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $831 From $813, Maintains Buy Rating

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic
REGN

GlobeNewswire

16 days ago

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
REGN

GlobeNewswire

16 days ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

REGN

MT Newswires

17 days ago

Sector Update: Health Care Stocks Higher Late Afternoon

REGN

MT Newswires

17 days ago

Sector Update: Health Care

Stock Market Today: Stocks rise despite Trump threats against Fed, tech regulation
REGN

TheStreet

17 days ago

Stock Market Today: Stocks rise despite Trump threats against Fed, tech regulation

The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)
REGN

Insider Monkey

17 days ago

The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)

REGN

MT Newswires

17 days ago

Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
REGN

GlobeNewswire

17 days ago

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Can Regeneron’s Value Shine Through After Recent Stock Slump in 2025?
REGN

Simply Wall St.

17 days ago

Can Regeneron’s Value Shine Through After Recent Stock Slump in 2025?

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles
REGN

Benzinga

18 days ago

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
REGN

GlobeNewswire

18 days ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
REGN

Motley Fool

19 days ago

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk
REGN

Zacks

21 days ago

The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk

J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub
REGN

Pharmaceutical Technology

22 days ago

J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub

FDA Extends Review Period of REGN's Submission for Eylea HD
REGN

Zacks

22 days ago

FDA Extends Review Period of REGN's Submission for Eylea HD

Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
REGN

Pharmaceutical Technology

22 days ago

Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD

J&J to invest $2 billion to boost US manufacturing as drug tariffs loom
REGN

Reuters

22 days ago

J&J to invest $2 billion to boost US manufacturing as drug tariffs loom

FDA Pushes Back Eylea HD Review; Regeneron Still Gains
REGN

GuruFocus.com

23 days ago

FDA Pushes Back Eylea HD Review; Regeneron Still Gains

REGN

MT Newswires

23 days ago

Regeneron Pharmaceuticals Says FDA Extends Action Dates for Eylea HD to Q4

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
REGN

GlobeNewswire

23 days ago

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

Will EXEL's Share Repurchase Program Boost Value for Investors?
REGN

Zacks

24 days ago

Will EXEL's Share Repurchase Program Boost Value for Investors?

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
REGN

GlobeNewswire

25 days ago

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
REGN

Zacks

a month ago

Can Eylea HD and Dupixent Profits Revive Regeneron Stock?

Financial Services Roundup: Market Talk
REGN

The Wall Street Journal

a month ago

Financial Services Roundup: Market Talk

'Big Short' investor Burry turned more bullish on second quarter
REGN

Reuters

a month ago

'Big Short' investor Burry turned more bullish on second quarter

Students Earn Top Awards at 42nd Annual Research Science Institute at MIT
REGN

GlobeNewswire

a month ago

Students Earn Top Awards at 42nd Annual Research Science Institute at MIT

Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares
REGN

Insider Monkey

a month ago

Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call
REGN

StockStory

a month ago

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
REGN

StockStory

a month ago

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
REGN

StockStory

a month ago

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810
REGN

Insider Monkey

a month ago

Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810

REGN

Investing.com

a month ago

Sanofi halts Praluent supply in China due to limited availability

Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners
REGN

Insider Monkey

a month ago

Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
REGN

Zacks

a month ago

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

REGN

MT Newswires

a month ago

Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
REGN

PR Newswire

a month ago

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
REGN

Zacks

a month ago

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

REGN

Morningstar Research

a month ago

Analyst Report: Intellia Therapeutics, Inc.

BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform
REGN

Insider Monkey

a month ago

BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform

Regeneron Announces Investor Conference Presentations
REGN

GlobeNewswire

a month ago

Regeneron Announces Investor Conference Presentations

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
REGN

Zacks

a month ago

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

REGN

Morningstar Research

a month ago

Analyst Report: Sanofi

Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25
REGN

PR Newswire

a month ago

Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25

Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
REGN

GlobeNewswire

a month ago

Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)

REGN

MT Newswires

a month ago

UBS Adjusts Regeneron Pharmaceuticals Price Target to $595 From $584, Maintains Neutral Rating

REGN

MT Newswires

a month ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $815 From $810, Maintains Buy Rating

REGN

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $785 From $804, Maintains Buy Rating

Manufacturing issues at Novo facility disrupt Regeneron drug review
REGN

Pharmaceutical Technology

a month ago

Manufacturing issues at Novo facility disrupt Regeneron drug review

Regeneron (REGN) Q2 Earnings: What To Expect
REGN

StockStory

a month ago

Regeneron (REGN) Q2 Earnings: What To Expect

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
REGN

GlobeNewswire

a month ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
REGN

Zacks

a month ago

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
REGN

Zacks

a month ago

Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
REGN

Zacks

a month ago

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)
REGN

Insider Monkey

a month ago

Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)

2 Healthcare Stocks That Are Losing to the S&P 500 This Year
REGN

Motley Fool

2 months ago

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip
REGN

Insider Monkey

2 months ago

Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
REGN

GlobeNewswire

2 months ago

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

3 Low-Volatility Stocks We Steer Clear Of
REGN

StockStory

2 months ago

3 Low-Volatility Stocks We Steer Clear Of

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP
REGN

PR Newswire

2 months ago

TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances
REGN

GlobeNewswire

2 months ago

Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
REGN

The Wall Street Journal

2 months ago

AstraZeneca Plans to Invest $50 Billion in U.S. by 2030

Health Canada extends Evkeeza approval for children with HoFH
REGN

Pharmaceutical Technology

2 months ago

Health Canada extends Evkeeza approval for children with HoFH

1 Healthcare Stock on Our Buy List and 2 to Brush Off
REGN

StockStory

2 months ago

1 Healthcare Stock on Our Buy List and 2 to Brush Off

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence
REGN

GlobeNewswire

2 months ago

Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments
REGN

GlobeNewswire

2 months ago

Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape
REGN

GlobeNewswire

2 months ago

Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape

REGN

MT Newswires

2 months ago

UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
REGN

Insider Monkey

2 months ago

Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
REGN

GlobeNewswire

2 months ago

Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights

Share on Social Networks: